Targeting HER2-positive breast cancer: advances and future directions

Sandra M. Swain(Roche (Switzerland)), Erika Hamilton(Sarah Cannon)
Nature Reviews Drug Discovery
November 7, 2022
10.1038/s41573-022-00579-0
Cited by 1,048

Related Papers

Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer
|Journal of Clinical Oncology|2006|523
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
|Journal of Clinical Oncology|2014|370
Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer
|Clinical Cancer Research|2004|68